Background: Most patients (pts) with ES-SCLC receive platinum-based chemotherapy with etoposide, however median survival is <1 y, and new options are needed. Here we assess the safety and clinical activity of the cancer immunotherapy atezo (anti-PDL1) as monotherapy in ES-SCLC. Methods: ES-SCLC pts received atezo IV q3w at 15 mg/kg or 1200 mg as part of a Ph Ia study (NCT01375842). Due to protocol amendments the first 5 pts were PD-L1 selected and the subsequent 12 were not PD-L1 selected.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile